Enhancing the activity of specific proteins involved in cancer signaling
Official title: Promoting Receptor Protein Tyrosine Phosphatase Activity by Targeting Transmembrane Domain Interactions
Funded at Lehigh University · NIH-10651834 · Data updated 2026-11-12
This study is looking at how specific proteins in our cells can help fight cancer by turning off harmful signals, and the goal is to find new treatments that make these proteins work better for people with cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lehigh University NIH-funded |
| Lab location | 1 site (Bethlehem, United States) |
| Project start | September 20, 2020 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $395,072 |
| NIH project number | 5R01GM139998-04 |
| Project ID | NIH-10651834 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with specific types of cancers that are influenced by receptor tyrosine kinases.
✕Less likely to help
Patients with non-malignant conditions or those whose cancers do not involve receptor tyrosine kinases may not benefit from this research.
What this research studies
This research investigates how certain proteins, known as receptor protein tyrosine phosphatases (RPTPs), regulate cell signaling that can lead to cancer. The team aims to understand the interactions between these proteins and their environment, particularly how they can be activated to counteract cancerous signals. By exploring the molecular mechanisms that control these proteins, the researchers hope to develop new therapies that enhance their activity against cancer-related pathways. This could lead to innovative treatments for patients with malignancies.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that improve cancer treatment by enhancing the body's natural signaling mechanisms.
How similar studies have gone: While the specific approach of targeting transmembrane domain interactions in RPTPs is relatively novel, similar strategies in cancer signaling have shown promise in other studies.
Where this research is happening
-
Lehigh University
Bethlehem, United States Active
Researchers
- Principal investigator: Thevenin, Damien — Lehigh University
- Study coordinator: Thevenin, Damien
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.